08
04
NRG PALLAS and Global Morpho Pharma Establish Strategic Partnership to Secure Independent Supply of Lutetium-177 Chloride
Petten, 31st March 2026 –
NRG PALLAS and Global Morpho Pharma (MORPHO) have entered into a strategic partnership to implement a sustainable and independent supply chain for n.c.a. Lutetium-177 chloride in Petten, NL.
Marjolijn Droog, Executive Director Medical Isotope Solutions, NRG PALLAS: “This partnership is a vital step toward a more resilient radiopharmaceutical ecosystem. By integrating Global Morpho Pharma’s technology with our infrastructure, we are creating a supply chain that is not just reliable, but truly independent, allowing innovation to flourish across the industry.”
By deploying KaLupso – MORPHO’s automated radiochemistry platform – within NRG PALLAS’s world-class nuclear infrastructure, the partnership directly addresses the global need for n.c.a. Lu-177 and accelerates patient access to next-generation cancer therapies.
François Zimmermann, CEO, Global Morpho Pharma: “Reliable isotope supply doesn’t happen by chance – it is engineered, through the right partnerships. NRG PALLAS brings world-class nuclear infrastructure and regulatory expertise, Global Morpho Pharma brings KaLupso, a fully automated, GMP-compliant platform for n.c.a. Lu-177 production. Combined, we offer the radiopharmaceutical industry a reliable, independent, and scalable source of supply.”
Addressing the Global Surge in Targeted Radionuclide Therapy
The primary objective of this partnership is to solve the critical supply bottleneck for Lutetium-177 (Lu-177), the most sought-after isotope in RadioLigand Therapy (RLT). In its GMP isotope production facility, NRG PALLAS will implement MORPHO’s proprietary KaLupso technology, an automated process to produce non-carrier-added lutetium chloride under Good Manufacturing Practices (GMP). This creates a robust, reliable, and sustainable source for this vital radiochemical.
A Unique Independent Supply Model
What distinguishes this collaboration is the commitment to an independent, non-exclusive supply model. NRG PALLAS and MORPHO will provide GMP-grade lutetium chloride to a broad spectrum of users – from established radiopharmaceutical giants to innovative public institutions and agile startups.
By combining mutual strengths in technology engineering, radiochemistry, and regulatory expertise, the partners offer unique competitive advantages:
- Integrated Infrastructure: NRG PALLAS operates a dedicated reactor and processing facility on the same premises in Petten.
- Optimized Yield: This co-location minimizes isotope decay during transport, ensuring maximum yield and cost-efficiency.
- Reliability: MORPHO’s KaLupso is a fully automated process, ensuring repeatable quality and performance.
- Market Leadership: The partnership sets a new industry standard for supply chain resilience.
The companies are currently installing, qualifying, and validating KaLupso within the GMP isotope production facility, with a target for initial commercial delivery in early 2027.
Impact on Patient Care
It is estimated that currently over 100,000 patients worldwide could benefit annually from Lu-177-based therapies. As these treatments move toward earlier lines of care, the eligible patient population is expected to grow exponentially. This partnership directly stimulates innovation, ensuring that these life-saving therapies reach patients faster and more reliably.
Targeted Cancer Treatment
Lutetium-177 is the cornerstone of RLT, a “search and destroy” method that delivers radiation directly to cancer cells while sparing healthy tissue. This partnership specifically targets the growing demand for treating:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC): One of the most common cancers in men globally.
- Neuroendocrine Tumors (NETs): Specifically those that are somatostatin receptor-positive.
- Emerging Indications: Ongoing clinical trials are expanding the use of Lu-177 to treat kidney, lung, and breast cancers.
About Global Morpho Pharma
Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes. It develops innovative equipment and builds efficient supply chains to enable its partners in France and abroad to manufacture or source nca Lu-177 and other radioisotopes of interest. Its team is dedicated to improving the accessibility and supply security of medical radioisotope for the benefit of patients, by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.
About NRG PALLAS
At NRG PALLAS, we are committed to improving people’s health and well-being through the use of nuclear technology. Advanced nuclear technology offers solutions for healthcare and clean energy supply. NRG PALLAS develops and supplies nuclear medical products and contributes to nuclear energy solutions. The High Flux Reactor, which will be replaced by the PALLAS reactor, is used to produce medical isotopes and conduct irradiation research on construction materials and fissile materials. NRG PALLAS is building the PALLAS reactor, which will secure the availability of the nuclear knowledge infrastructure and thus its impact on health and energy for the future.